On August 28, 2026 NeOnc Technologies Holdings (NASDAQ: NTHI), reported the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 12, NeOnc reported positive topline results from the NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company reported 48.9% six-month progression-free survival, substantially above the prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was reported at 26.09 months, while 86.7% of patients were alive at six months. Five of the 24 patients remained on treatment, including one patient with a partial response continuing beyond 114 days.

Those figures are still clinical-stage evidence, not proof of efficacy sufficient for approval, and the open-label Phase 2a design creates important limitations. Yet, they represent a significant change in the information available to investors. NeOnc now has a defined clinical dataset, survival information and, importantly, a specific regulatory objective: the company plans to request a Type B meeting with the FDA to discuss a potential registrational pathway for NEO100.

That meeting could become the next major catalyst because it may help determine what the FDA would require to move the program forward. In other words, the investment question could be shifting from "Does NEO100 work?" to "What would it take to get NEO100 to a potential approval?"

The science behind the program gives that question additional weight. NEO100 is an intranasal formulation of purified perillyl alcohol being developed for CNS cancers. NeOnc’s strategy is designed around delivering therapy through the nasal route while addressing the challenges associated with treating tumors in the brain. The company is also developing NEO212, which has completed Phase 1 and established a recommended Phase 2 dose of 610 mg.

NeOnc had already described the August clinical readout as "one of the most important clinical milestones in NeOnc’s history." The subsequent data provide context for that statement, while the upcoming FDA interaction could determine whether the milestone becomes a foundation for the next stage of development.

There are other signals worth watching. In June, NeOnc announced UAE IND approvals for NEO100 and NEO212, covering adult and pediatric development programs. The company said the NEO100 authorization encompasses three clinical programs ranging from Phase 1 through Phase 2. Meanwhile, CEO Amir Heshmatpour has continued reporting open-market purchases of NTHI shares, following earlier buying and more than $500,000 in previously disclosed purchases. Director Thomas Chen, M.D., Ph.D. also reported purchasing 33,787 shares at $3.8477 on August 14 and another 2,472 shares at $4.0445 on August 17, according to the provided SEC filing information.

That creates interesting market dynamics, but the fundamental catalyst remains the company’s ability to translate clinical results into regulatory progress and that is ultimately what makes the current setup different.

NeOnc remains a clinical-stage biotechnology company, with substantial risks involving additional trials, regulatory review, financing, manufacturing, competition and eventual commercialization. Phase 2a results do not guarantee a successful registrational study or FDA approval.

However, NEO100 has now crossed an important threshold, by reporting that its primary endpoint was achieved, six-month PFS substantially exceeded its prespecified benchmark, median overall survival reached 26.09 months, and management is preparing to engage the FDA about a potential registrational strategy.

For NTHI, the next headline may matter more than the last one. The clinical question produced a meaningful answer. Now the regulatory question takes center stage.

(Press release, Neonc, AUG 28, 2026, View Source [SID1234670421])